Showing results (411-420 of 493) with videos related to

Sort By:
Pageof 50
BMC Neurology|December 14, 2020
Discussing personalized prognosis in amyotrophic lateral sclerosis: development of a communication guideRemko M van Eenennaam, Willeke J Kruithof, Michael A van Es, et al.
Clinical Pharmacology in Drug Development|June 12, 2019
Effect of Food on the Pharmacokinetics of 2 Formulations of DRL-17822, a Novel Selective Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy MalesAnnelieke C Kruithof, Rajinder Kumar, Jasper Stevens, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|June 16, 2009
Maternal anthropometrics are associated with fetal size in different periods of pregnancy and at birth. The Generation R StudyL Ay, C J Kruithof, R Bakker, et al.
Journal of Hepatology|May 7, 2005
The RL-ET-14 cell line mediates expression of glutamine synthetase through the upstream enhancer/promoter regionMarianna Kruithof-de Julio, Wilhelmina T Labruyère, Jan M Ruijter, et al.
Journal of Clinical Pharmacology|July 31, 2025
Osimertinib Cost Minimization in Non-Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination With CobicistatNiels Westra, Paul D Kruithof, Sander Croes, et al.
Annals of the Rheumatic Diseases|November 18, 2004
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestationsL De Rycke, I Peene, I E A Hoffman, et al.
BMC Medical Genomics|October 9, 2015
RNA sequencing reveals a depletion of collagen targeting microRNAs in Dupuytren's diseaseScott M Riester, Diren Arsoy, Emily T Camilleri, et al.
The Journal of Clinical Endocrinology and Metabolism|June 8, 2006
A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin-like growth factor I receptorM J E Walenkamp, H J van der Kamp, A M Pereira, et al.
Frontiers in Oncology|February 22, 2021
Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor HeterogeneityFederico La Manna, Marta De Menna, Nikhil Patel, et al.
Frontiers in Oncology|July 14, 2020
Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor HeterogeneityFederico La Manna, Marta De Menna, Nikhil Patel, et al.
Pageof 50